Attune Pharmaceuticals raised $23 million in series B financing to push its oral drug for hereditary angioedema through phase 2.
The FDA has placed a clinical hold on the IND for Translate Bio’s mRNA treatment for ornithine transcarbamylase deficiency.
In this paper, we discuss some of the risks associated with the supply chain as well as the characteristics of a technology solution that can help you mitigate…
Why Bosley is leaving and whether she has another job lined up is not being made public.
A phase 1b study of Sorrento’s nerve-ablating painkiller showed rapid relief of osteoarthritic knee pain, and lasted for nearly 3 months.
Fresh from reporting clinical data at ASH, Immunochina has raised $20 million to speed up its CAR-T development programs.
VOS failed to best the tolerability of Allergan's Restasis but delivered superior efficacy, suggesting it may have an unexpected edge over its rival.
Gamida Cell brought on a subsidiary of the National Marrow Donor Program to support a phase 3 study of its blood cancer cell therapy alternative.
Wren Therapeutics will use the series A round to advance its research into drugs to treat protein-misfolding diseases such as Alzheimer’s.
A Fred Hutch team has figured out how to kill dormant breast cancer cells using compounds that disrupt a protective signaling system.
Kaia Health, makers of smartphone apps for home treatment of chronic conditions, raised $10 million in funding for its U.S. rollout.